Oct 07, 2016

How a Promising New Approach Attacks the Roots of Cancer

Cancer stem cells – the roots of tumors – perpetuate tumor growth and spread; understanding them may hold the key to treating cancer in the future. Learn more from Scott J. Dylla, chief scientific officer of AbbVie Stemcentrx.
Sep 27, 2016

AbbVie Repeats as a Working Mother “100 Best Company”

For the fourth consecutive year, AbbVie has made Working Mother magazine’s list of “100 Best Companies.

Sep 22, 2016

Protecting the Earth, One Pound of CO2 at a Time

Energy management has been the unseen hero of the sustainability world. Now, it’s finally getting its time in the (energy efficient) spotlight. 

Sep 20, 2016

14 Ways Your Donation Helps Real People

When you donate to a worthy cause, you want to know exactly how that contribution helps real people.
Sep 16, 2016

What We’re Learning from Alzheimer’s Research and How Biomarkers May Help

Hope and expectation have never met more frequently with disappointment in clinical trial research for Alzheimer’s disease. But the question is, why? 

Sep 08, 2016

AbbVie Leads Industry in Dow Jones Sustainability World Index

AbbVie is the industry leader in Dow Jones Sustainability World Index with the highest score of 34 biotechnology companies.
Sep 02, 2016

The Surprising Reasons People Don’t Do What the Doctor Ordered

Half of all people with chronic diseases don’t take their medications as directed. Finding out why is only half the battle.

Aug 05, 2016

World-Renowned Soccer Star Tackles a New Challenge

For soccer star Brandi Chastain, having a game plan was second nature, until last year when she had to tackle a different type of plan.



Oct 19, 2016

AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual and Non-Menstrual Pelvic Pain Associated with Endometriosis at the American Society for Reproductive Medicine Scientific Congress

NORTH CHICAGO, Ill., Oct. 19, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis. The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain (NMPP) associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale. The results were presented at the 72nd American Society for Reproductive Medicine Scientific Congress & Expo (ASRM) in Salt Lake City, as well as additional abstracts.

Oct 14, 2016

AbbVie Receives CHMP Positive Opinion for VENCLYXTO™ (venetoclax) Tablets for Appropriate Patients with Difficult-To-Treat Chronic Lymphocytic Leukaemia

- CHMP recommends VENCLYXTO monotherapy for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemo-immunotherapy and a B-cell receptor pathway inhibitor

Oct 10, 2016

AbbVie to Host Third-Quarter Earnings Conference Call

NORTH CHICAGO, Ill., Oct. 10, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2016 financial results on Friday, October 28, 2016, before the market opens.